alk f1174l

ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).

JH-VIII-157-02 is an inhibitor of ALK and inhibits echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) with IC50s of 2 nM for EML4-ALK G1202R, EML4-ALKwt, EML4-ALK C1156Y, EML4-ALK F1174L, and EML4-ALK F1174L.

Alectinib hydrochloride (RO5424802 Hydrochloride) is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM)

Alectinib (RG-7853) is an ALK inhibitor (IC50=1.9 nM, Kd=2.4 nM) that is selective, orally active, and ATP-competitive. Alectinib has antitumor activity and is used in the treatment of non-small cell lung cancer.

KF-20444 is an orally active ALK inhibitor with the ability to penetrate the blood-brain barrier. It exhibits potent inhibitory effects on ALK fusion proteins (EML4-ALK) and ALK-resistant mutations, including L1196M, G1202R, and F1174L. KF-20444 effectively suppresses the phosphorylation of ALK in cancer cell lines driven by ALK, thereby inhibiting cancer cell proliferation and inducing apoptosis (apoptosis). In mouse models bearing ALK-positive non-small cell lung cancer or neuroblastoma, it demonstrates antitumor efficacy. KF-20444 is applicable for research into ALK-driven malignancies.

ALK/HDAC-IN-2 (Compound 19b) functions as an ALK/HDAC inhibitor, demonstrating IC₅₀ values of 8 nM for ALK WT and 1.18 μM for total HDACs. It is effective against ALK mutants G1202R, F1174L, and L1196M, with IC₅₀ values of 2.74, 9.23, and 34.28 nM, respectively. The compound shows potent and selective inhibition of HDAC1 (IC₅₀= 0.24 μM), while exhibiting weak inhibition against HDAC7, HDAC6, and HDAC11 (IC₅₀> 10 μM). Additionally, ALK/HDAC-IN-2 has broad-spectrum antiproliferative effects on various cancer cell lines, inducing cell cycle arrest and apoptosis. This compound is applicable for neuroblastoma research.

Ensartinib (X-396) is a potent and orally active dual ALK/MET inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).

Trk-IN-7 (compound I-6) is a highly potent TRK inhibitor, with IC50 values of 0.25-10 nM for TRKA, TRKB, and TRKC, respectively. It also shows significant inhibition of EML4-ALK (IC50 <15 nM) and ALK mutations G1202R, C1156Y, R1275Q, F1174L, L1197M, and G1269A (IC50 = 5-50 nM) [1].

Alectinib-D8 is a deuterated compound of Alectinib. Alectinib (T1936) has a CAS number of 1256580-46-7. CH5424802 is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.

Alectinib hydrochloride (Standard) is a reference standard for research and analysis in studies involving Alectinib hydrochloride. Alectinib hydrochloride (RO5424802 Hydrochloride) is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM)

Alectinib-D8 (Standard) is a reference standard of Alectinib-D8 intended for quantitative analysis, quality control, and related biochemical research applications. Alectinib-d8 is a deuterated compound of Alectinib. Alectinib has a CAS number of 1256580-46-7. CH5424802 is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.